相似文献
1
PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment.
Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1117-8. doi: 10.1081/NCN-200027377.
2
The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
J Clin Pharmacol. 2006 Jan;46(1):88-102. doi: 10.1177/0091270005282634.
3
Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers.
Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1111-6. doi: 10.1081/NCN-200027372.
4
The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
J Clin Pharmacol. 2008 Sep;48(9):1014-24. doi: 10.1177/0091270008322035. Epub 2008 Jul 17.
5
Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia.
Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1119-22. doi: 10.1081/NCN-200027381.
6
A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study.
J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S27-34. doi: 10.1097/RHU.0b013e31821d36f2.
7
Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
Clin Pharmacokinet. 2006;45(8):821-41. doi: 10.2165/00003088-200645080-00005.
8
Urate-lowering therapy for gout: focus on febuxostat.
Pharmacotherapy. 2010 Jun;30(6):594-608. doi: 10.1592/phco.30.6.594.
9
Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment.
Am J Ther. 2005 Jan-Feb;12(1):22-34. doi: 10.1097/00045391-200501000-00005.
10
Febuxostat: drug review and update.
Expert Opin Drug Metab Toxicol. 2014 May;10(5):747-58. doi: 10.1517/17425255.2014.904285. Epub 2014 Apr 1.
引用本文的文献
1
An integrated population pharmacokinetic model of febuxostat in pediatric patients with hyperuricemia including gout and adult population of healthy subjects and patients with renal dysfunction.
Pharmacol Res Perspect. 2024 Dec;12(6):e70032. doi: 10.1002/prp2.70032.
2
Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
Clin Rheumatol. 2021 Feb;40(2):683-692. doi: 10.1007/s10067-020-05272-4. Epub 2020 Jul 11.
3
Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
Int Urol Nephrol. 2019 Mar;51(3):467-473. doi: 10.1007/s11255-018-2051-2. Epub 2019 Jan 2.
4
Side Effects and Interactions of the Xanthine Oxidase Inhibitor Febuxostat.
Pharmaceuticals (Basel). 2018 May 25;11(2):51. doi: 10.3390/ph11020051.
5
Spontaneous Tumor Lysis Syndrome in Small-Cell Lung Cancer: A Rare Complication.
World J Oncol. 2015 Oct;6(5):464-471. doi: 10.14740/wjon946w. Epub 2015 Oct 26.
6
Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat.
Clin Pharmacokinet. 2017 May;56(5):459-475. doi: 10.1007/s40262-016-0466-4.
7
Increase in thyroid stimulating hormone levels in patients with gout treated with inhibitors of xanthine oxidoreductase.
Rheumatol Int. 2015 Nov;35(11):1857-61. doi: 10.1007/s00296-015-3355-5. Epub 2015 Sep 5.
8
The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study.
Trials. 2014 Jan 16;15:26. doi: 10.1186/1745-6215-15-26.
9
Tumor lysis syndrome: new challenges and recent advances.
Adv Chronic Kidney Dis. 2014 Jan;21(1):18-26. doi: 10.1053/j.ackd.2013.07.001.
10
Bioequivalance and pharmacokinetic study of febuxostat in human plasma by using LC-MS/MS with liquid liquid extraction method.
Springerplus. 2013 Apr 30;2(1):194. doi: 10.1186/2193-1801-2-194. Print 2013 Dec.
Zotero 插件